VSTM saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 04, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 40 instances where the indicator turned negative. In 38 of the 40 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VSTM as a result. In 71 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
VSTM moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VSTM crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VSTM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where VSTM advanced for three days, in 204 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
VSTM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. VSTM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.237) is normal, around the industry mean (3.596). P/E Ratio (-3.447) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 90 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VSTM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ZYME advanced for three days, in 252 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for ZYME crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 72%.
ZYME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 186 of 221 cases where ZYME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
The 10-day RSI Indicator for ZYME moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 53 similar instances where the indicator moved out of overbought territory. In 39 of the 53 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZYME as a result. In 68 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for ZYME turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 39 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
ZYME moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.452) is normal, around the industry mean (3.596). P/E Ratio (-14.668) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (52.910) is also within normal values, averaging (443.347).
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
VSTM | ZYME | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 71 | 37 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 88 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 57 | 48 | |
P/E GROWTH RATING 1..100 | 90 | 78 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VSTM's Valuation (82) in the Biotechnology industry is in the same range as ZYME (83) in the Pharmaceuticals Major industry. This means that VSTM’s stock grew similarly to ZYME’s over the last 12 months.
ZYME's Profit vs Risk Rating (88) in the Pharmaceuticals Major industry is in the same range as VSTM (100) in the Biotechnology industry. This means that ZYME’s stock grew similarly to VSTM’s over the last 12 months.
ZYME's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as VSTM (100) in the Biotechnology industry. This means that ZYME’s stock grew similarly to VSTM’s over the last 12 months.
ZYME's Price Growth Rating (48) in the Pharmaceuticals Major industry is in the same range as VSTM (57) in the Biotechnology industry. This means that ZYME’s stock grew similarly to VSTM’s over the last 12 months.
ZYME's P/E Growth Rating (78) in the Pharmaceuticals Major industry is in the same range as VSTM (90) in the Biotechnology industry. This means that ZYME’s stock grew similarly to VSTM’s over the last 12 months.
| VSTM | ZYME | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 80% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 77% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 78% |
| Advances ODDS (%) | 11 days ago 82% | 3 days ago 85% |
| Declines ODDS (%) | 2 days ago 86% | 9 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 80% |
| Aroon ODDS (%) | N/A | 2 days ago 84% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
VSTM’s FA Score shows that 0 FA rating(s) are green while ZYME’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
VSTM’s TA Score shows that 4 TA indicator(s) are bullish while ZYME’s TA Score has 5 bullish TA indicator(s).
VSTM (@Biotechnology) experienced а -22.62% price change this week, while ZYME (@Biotechnology) price change was -0.38% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.
VSTM is expected to report earnings on Mar 18, 2027.
ZYME is expected to report earnings on Mar 10, 2027.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with REPL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then REPL could also see price increases.
| Ticker / NAME | Correlation To ZYME | 1D Price Change % | ||
|---|---|---|---|---|
| ZYME | 100% | -2.68% | ||
| REPL - ZYME | 46% Loosely correlated | -0.83% | ||
| DYN - ZYME | 44% Loosely correlated | -3.31% | ||
| BCYC - ZYME | 40% Loosely correlated | -4.92% | ||
| ENTA - ZYME | 40% Loosely correlated | -4.51% | ||
| VIR - ZYME | 40% Loosely correlated | -5.41% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SRS | 42.81 | 0.80 | +1.90% |
| ProShares UltraShort Real Estate (SRS) | |||
| GJS | 23.35 | 0.06 | +0.27% |
| Synthetic Fixed-Income Securities STRATS 2006-2 Goldman Sachs Group | |||
| AUGM | 34.85 | -0.05 | -0.16% |
| FT Vest U.S. Equity Max Buffer ETF - August (AUGM) | |||
| QEFA | 94.84 | -1.64 | -1.70% |
| State Street SPDR MSCI EAFE StrategicFactors ETF (QEFA) | |||
| WOOD | 61.27 | -1.25 | -1.99% |
| iShares Global Timber & Forestry ETF (WOOD) | |||